Glaukos Corporation $GKOS Stock Position Lowered by Vanguard Group Inc.

Vanguard Group Inc. decreased its stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 0.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,965,115 shares of the medical instruments supplier's stock after selling 9,856 shares during the quarter. Vanguard Group Inc. owned about 10.44% of Glaukos worth $587,087,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Westfield Capital Management Co. LP raised its stake in shares of Glaukos by 34.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier's stock valued at $106,705,000 after acquiring an additional 277,033 shares in the last quarter. Gilder Gagnon Howe & Co. LLC lifted its stake in Glaukos by 25.3% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier's stock worth $123,742,000 after acquiring an additional 166,677 shares during the last quarter. Northern Trust Corp grew its holdings in Glaukos by 7.4% during the 4th quarter. Northern Trust Corp now owns 578,673 shares of the medical instruments supplier's stock worth $86,766,000 after acquiring an additional 40,052 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Glaukos by 21.8% in the 1st quarter. Principal Financial Group Inc. now owns 327,036 shares of the medical instruments supplier's stock valued at $32,187,000 after purchasing an additional 58,502 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its position in shares of Glaukos by 0.9% during the 4th quarter. Nuveen Asset Management LLC now owns 314,963 shares of the medical instruments supplier's stock worth $47,226,000 after purchasing an additional 2,665 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on GKOS. William Blair raised Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Truist Financial reissued a "buy" rating and issued a $135.00 target price (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Morgan Stanley decreased their price target on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Mizuho set a $130.00 target price on shares of Glaukos in a research note on Thursday, July 31st. Finally, Stifel Nicolaus decreased their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $127.42.

Glaukos Stock Up 0.4%

NYSE:GKOS traded up $0.37 during trading hours on Monday, hitting $90.23. The stock had a trading volume of 115,200 shares, compared to its average volume of 957,504. The business has a 50 day simple moving average of $96.84 and a two-hundred day simple moving average of $102.97. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The company has a market cap of $5.17 billion, a PE ratio of -54.66 and a beta of 0.78. Glaukos Corporation has a 1-year low of $77.10 and a 1-year high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02. The company had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm's revenue for the quarter was up 29.7% compared to the same quarter last year. During the same period last year, the business earned ($0.52) EPS. Analysts predict that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.